Patents by Inventor Randall Mrsny
Randall Mrsny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11865093Abstract: Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.Type: GrantFiled: July 13, 2018Date of Patent: January 9, 2024Assignees: University of Massachusetts, University of BathInventors: Randall Mrsny, Beth McCormick, Roland Ellwood Dolle
-
Publication number: 20200138756Abstract: Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.Type: ApplicationFiled: July 13, 2018Publication date: May 7, 2020Inventors: Randall Mrsny, Beth McCormick, Ronald Ellwood Dolle
-
Publication number: 20180353610Abstract: The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. Importantly, the systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.Type: ApplicationFiled: December 11, 2017Publication date: December 13, 2018Applicant: Applied Molecular Transport, LLCInventors: Randall Mrsny, Tahir Mahmood
-
Patent number: 10130688Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.Type: GrantFiled: June 7, 2017Date of Patent: November 20, 2018Assignee: Applied Molecular Transport Inc.Inventors: Randall Mrsny, Tahir Mahmood
-
Publication number: 20170281736Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.Type: ApplicationFiled: June 7, 2017Publication date: October 5, 2017Applicant: Applied Molecular Transport, LLCInventors: Randall Mrsny, Tahir Mahmood
-
Publication number: 20150265718Abstract: The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. Importantly, the systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicant: Applied Molecular Transport, LLCInventors: Randall Mrsny, Tahir Mahmood
-
Publication number: 20150265719Abstract: The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. Importantly, the systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.Type: ApplicationFiled: June 8, 2015Publication date: September 24, 2015Applicant: Applied Molecular Transport, LLCInventors: Randall Mrsny, Tahir Mahmood
-
Publication number: 20070148131Abstract: The present invention relates, in part, to methods and compositions for needleless delivery of macromolecules to a subject. In one aspect, the methods and compositions involve administering to the subject a delivery construct comprising a carrier construct non-covalently bound to a binding partner, wherein the carrier construct comprises a receptor-binding domain, a transcytosis domain, and a macromolecule to which the binding partner non-covalently binds, wherein the binding partner binds to the macromolecule with a Ka that is at least about 104 M?1.Type: ApplicationFiled: December 5, 2006Publication date: June 28, 2007Applicant: Trinity Biosystems, Inc.Inventor: Randall Mrsny
-
Publication number: 20070141070Abstract: The present invention relates, in part, to methods and compositions for needleless delivery of antibodies to a subject. The present invention also relates, in part, to methods for needleless delivery of fusion proteins comprising a bioactive molecule and an antibody fragment to subject. In one aspect, the methods and compositions involve administering to the subject a delivery construct comprising a carrier construct non-covalently bound to the antibody or fusion protein to be delivered, wherein the carrier construct comprises a receptor-binding domain, a transcytosis domain, and an antibody-binding domain to which the antibody or the antibody fragment of the fusion protein non-covalently binds.Type: ApplicationFiled: December 5, 2006Publication date: June 21, 2007Applicant: Trinity Biosystems, Inc.Inventor: Randall Mrsny
-
Publication number: 20060153798Abstract: Methods and compositions for needleless delivery of macromolecules to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a macromolecule to be delivered to a subject, and a cleavable linker. In certain aspects, the cleavable linker can be cleavable by an enzyme present in higher concentration at or near the basal-lateral membrane of a polarized epithelial cell or in the plasma than elsewhere in the body, for example, at the apical side of the polarized epithelial cell. In other aspects, the invention provides nucleic acids encoding delivery constructs of the invention, kits comprising delivery constructs of the invention, cells expressing delivery constructs of the invention, and methods of using delivery constructs of the invention.Type: ApplicationFiled: October 4, 2005Publication date: July 13, 2006Inventor: Randall Mrsny
-
Publication number: 20060104993Abstract: Methods and compositions for inducing an immune response against Pseudomonas aeruginosa are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and a Pseudomonas pilin peptide comprising an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), wherein the chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said Pseudomonas pilin peptide to epithelial cells of said subject. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods of using chimeric immunogens of the invention.Type: ApplicationFiled: October 4, 2005Publication date: May 18, 2006Inventor: Randall Mrsny
-
Publication number: 20050261196Abstract: Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use.Type: ApplicationFiled: April 21, 2005Publication date: November 24, 2005Applicants: The University of Chicago, University College Cariff Consultants Ltd., McMaster UniversityInventors: Jerrold Turner, Randall Mrsny, Derek McKay
-
Publication number: 20050079171Abstract: This invention provides methods of eliciting a secretry IgA-mediated immune response in a subject by administering a Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Compositions comprising secretory IgA antibodies that specifically recognize an epitope of HIV-1 also are provided.Type: ApplicationFiled: September 9, 2003Publication date: April 14, 2005Applicants: The Government of the USA as represented by the Secretary of the Dept. of Health & Human Services, Genentech, Inc.Inventors: David FitzGerald, Randall Mrsny
-
Publication number: 20040265323Abstract: The present invention relates to the use of eiconosoid hepoxilin A3 to modulate epithelial transmigration of inflammatory cells. The present invention further relates to pharmaceutical compositions comprising native hepoxilin A3, hepoxilin A3 analogs, or specific inhibitors thereof, as well as inhibitors of the biosynthetic pathway of hepoxilin A3. Compositions and methods of the present invention are useful for enhancing cellular immunity or treating disorders associated with epithelial inflammation.Type: ApplicationFiled: May 17, 2004Publication date: December 30, 2004Inventors: Beth A. McCormick, Randall Mrsny, James L. Madara